Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Thoughts??

<< Previous

Bullboard Posts

Next >>

Comment by crow27on Nov 13, 2020 8:04pm

203 Views

Post# 31900145

RE:RE:Thoughts??

I agree with that. A buyer will not mind paying more once the all clear is given. ATE has a great product that is coming together at the right time. EVERONE knows we need a new product as the old ones are way to harmfull.
You know how it goes ......................... nobody wants a stock until everybody wants the stock!!
Will not pay .40 cents but will pay $2.00 all day long. But at $2.00 there might be alot less risk.
We did not have a splash of an opening on the TSX but it will come. The PR machine will be firing on all 12 cylinders soon enough.
If you can pick up a few more in this range. ATE could very well look a lot different by Xmas.

<< Previous

Bullboard Posts

Next >>

Three stocks with strong income statements to buy right now